Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05086692 · ClinicalTrials.gov registry record · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
A Phase 1 study of Advanced Solid Tumor and Gastric Cancer, sponsored by Medicenna Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
- 20
- Study locations
NCT05086692 is a Phase 1 study of Advanced Solid Tumor and Gastric Cancer that is actively recruiting participants, run by Medicenna Therapeutics. The registered enrollment target is 115 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05086692, a Phase 1 study of Advanced Solid Tumor and Gastric Cancer, is actively recruiting participants, sponsored by Medicenna Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG MDNA11
- DRUG Pembrolizumab (KEYTRUDA®)
Study Locations (20)
Other
- Mater Misericordiae University Hospital - Dublin
- START Lisbon - Centro de Ensaios Clínicos, ULS Sta Maria - Lisbon
- Instituto Portugues De Oncologia Do Porto - Porto
- Institut Catala d'Oncologia (ICO)-Badalona - Badalona
California
- Sharp Memorial Hospital - San Diego
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- Providence Saint John's Health Center - Santa Monica
New South Wales
- Scientia Clinical Research - Randwick
- Macquarie University - Sydney
Queensland
- University of the Sunshine Coast - Buderim
- Gallipoli Medical Research Foundation - Greenslopes
Gyeonggi-do
- Seoul National University Bundang Hospital - Seongnam-si
- The Catholic University of Korea St. Vincent Hospital - Suwon
Florida
- Boca Raton Regional Hospital - Boca Raton
Georgia
- Emory - Winship Cancer Institute - Atlanta
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05086692
The ClinicalTrials.gov registry entry for NCT05086692 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (40% lower). The listed sponsor is Medicenna Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which MDNA11 is the first listed.
NCT05086692 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, New South Wales.
Frequently Asked Questions
What is clinical trial NCT05086692 about?
NCT05086692 is a clinical study titled "A Beta-only IL-2 ImmunoTherapY Study". This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
What is the current status of trial NCT05086692?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2021-08-27. Estimated completion is 2026-12-30.
What conditions does trial NCT05086692 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Gastric Cancer, Cervical Cancer, Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT05086692?
The interventions under investigation include: MDNA11 (DRUG), Pembrolizumab (KEYTRUDA®) (DRUG).
Who is sponsoring clinical trial NCT05086692?
This trial is sponsored by Medicenna Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05086692 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.